Reefrad, I haven’t kept up with with board so I appreciate you sharing your conversation, and I apologize if I wasn’t very clear. I agree with your characterization of Dave as genuine and honest, and I think he is extremely knowledgable about the industry and markets, which is why I find it curious that he said that “the clinical trials update is a nothing burger and meaningless.“
I personally think that updating the clinical trials registry is a pretty big deal, and I believe it’s a prerequisite for the journal article, so I’m not sure why he is saying that it’s not related and is downplaying the significance. The timing of the update occurred when it did for a reason, and I don’t believe that it was just some afterthought to clear things up. Northwest Bio has been slow and deliberative in their actions and disclosures. So whether it’s for regulatory reasons, or they are gathering evidence for an investigation, or something else, I think there are likely valid reasons for the way things have played out this past week, but it appears Dave and Northwest Bio are not able to disclose this right now, and perhaps don’t want to draw attention to it.
Market Data 
Markets 
AI
